Skip to main content

Table 3 Model cost parameters presented in 2018 RMB

From: Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technology

Parameters

Mean

Reference

Screening by IF for PKU(per newborn)

23

Field investigation

Screening by IF for CH(per newborn)

23

Field investigation

Screening by IF for CAH(per newborn)

23

Field investigation

Screening by IF for G6PD(per newborn)

23

Field investigation

Screening by MS/MS (per newborn)

296

Field investigation

Confirmation by IF (per newborn)

319

Field investigation

Confirmation by MS/MS (per newborn)

296

Field investigation

Treatment for the diseases (per person-year)a

Age groupsb

0 ~ 5 years

6 ~ 82 years

Guidelines for the Treatment of Rare Diseases (2019) [64]

MSUD

13,440.90

6083.00

HCY

13,772.13

5952.51

CIT I、CIT II

48,202.46

20,833.77

IVA

17,567.81

13,045.01

GA I

17,567.81

13,045.01

MMA

19,023.76

24,692.53

PA

17,567.81

19,839.39

MCAD, PCD, VLCAD

15,853.26

15,853.26

PKU

15,000.00

15,000.00

Field investigation

Treatment for sequelae (per person-year)c

DD

3,064

[65]

ND

53,400

[66]

MR

12,000

[67]

RD

70,213

[68]

Follow-up (per person-year)

IF (4 times)

1,276

Field investigation

MS/MS(4 times)

1,184

Field investigation

Transportation (per year)

435

Field investigation

Lost productivity (per year)

3,060

[69]

Program cost

Sample transportation (per year)

42,000

Field investigation

Printing (per year)

340,000

Cold-chain logistics (per year)

470,000

Software development and maintenance, equipment updating, etc (per year)

370,000

Utilities (per person-year)

2.52

[70], supposing 200,000 people are screened

Administrative management (per person-year)

1.81

Depreciation of buildings, equipment, etc

Sunk costs

  1. aThe calculation process of the treatment cost of the diseases is detailed in Additional file 2
  2. bSchoen et al. [57] divide the cost of treatment into two parts at 5 years of age since, in some cases, additional care is needed for children with IEMs detected after symptoms manifest during their first five years. We also found discrepancies between different ages in the treatment and medication criteria for IEMs when referring to Guidelines for the Treatment of Rare Diseases (2019). Therefore, we did the same work to estimate the treatment cost by dividing patients into two groups at age 5
  3. cDD Development Delay, ND Neurological Damage, MR Mental Retardation, RD Renal Damage